Every story in this section, newest first — page 47 of 373.
Fate Therapeutics (NASDAQ:FATE) received a $15 million grant from the California Institute for Regenerative Medicine to support the Phase 2 RECLAIM-LN clinical trial evaluating FT819, an off-the-shelf CAR T-cell therapy.
Madison Dearborn Partners agreed to acquire The Marygold Companies (NYSE:MGLD) in an all-cash transaction that values each outstanding share at $2.00 and will take the financial services company private.
AstraZeneca (NASDAQ:AZN) received U.S. Food and Drug Administration Priority Review for its supplemental Biologics License Application for IMFINZI (durvalumab) combined with enfortumab vedotin in patients with muscle-invasive bladder cancer who are ineligible for or have declined cisplatin-based chemotherapy.
Johnson & Johnson (NYSE:JNJ) reported five-year CARTITUDE-2 study results showing that 10 of 20 patients treated with CARVYKTI remained alive and progression-free without maintenance therapy after receiving a single infusion.
Merck (NYSE:MRK) and Eisai received U.S. Food and Drug Administration approval for the combination of WELIREG (belzutifan) and LENVIMA (lenvatinib) to treat adults with advanced clear cell renal cell carcinoma after PD-1 or PD-L1 inhibitor therapy.
Duke Energy (NYSE:DUK) appointed Joyce Mullen to its board of directors effective September 28, 2026, with Mullen joining the Audit Committee and Operations and Nuclear Oversight Committee.
Addex Therapeutics (NASDAQ:ADXN) announced it regained full global rights to its GABAB positive allosteric modulator assets from Indivior UK, including a development candidate previously selected under their research collaboration.
Johnson Outdoors (NASDAQ:JOUT) announced that its board of directors approved a quarterly cash dividend of $0.33 per Class A share and $0.30 per Class B share, payable on October 23, 2026.
Vertical Aerospace (NYSE:EVTL) opened a dedicated Aircraft Assembly Centre at its Cotswold Airport Flight Test Centre, adding 60,000 square feet of manufacturing space to support the development and production of its Valo electric vertical take-off and landing aircraft.
Akamai Technologies (NASDAQ:AKAM) shares rose 21% premarket after the company signed an $11.6 billion, seven-year cloud services agreement with AI company Anthropic, with the deal including a warrant that could allow Anthropic to acquire a stake of up to 5% in Akamai.
WhiteHawk Minerals Corp. (NYSE:WHK) announced the closing of approximately $111.8 million in acquisitions, including the $105 million purchase of Marcellus, Utica, and Haynesville Shale natural gas mineral and royalty assets from San Jacinto Minerals II.
Oil prices moved lower on Friday as investors balanced expectations for possible progress in US-Iran negotiations against concerns that continued attacks in the Middle East could disrupt crude supplies.
REGENXBIO (NASDAQ:RGNX) announced three-year Phase II results from the ALTITUDE clinical trial evaluating investigational sura-vec for non-proliferative diabetic retinopathy (NPDR).
CenterPoint Energy (NYSE:CNP) announced that its Board of Directors has declared a regular quarterly cash dividend of $0.2400 per share on the company’s issued and outstanding common stock.
Global investment firm KKR (NYSE:KKR) announced that funds managed by the company have completed the sale of a portfolio of 16 hotels across Japan operating under the Four Points Flex by Sheraton brand.
ArcelorMittal (NYSE:MT) announced that it cannot safely and sustainably restart operations at its Kryvyi Rih subsidiary in Ukraine following continued damage from missile strikes.
FingerMotion (NASDAQ:FNGR) announced that it has received indications of interest representing approximately 52.5 MW of potential demand for its Alberta power-and-compute program.
Oracle (NYSE:ORCL) shares declined on Thursday following reports that the company has taken steps to reduce its financial exposure to a major artificial intelligence data center project in New Mexico.
Upbound Group (NASDAQ:UPBD) announced that its Board of Directors has approved a quarterly cash dividend of $0.39 per common share for the fourth quarter of 2026.
Mesoblast (NASDAQ:MESO) announced that the U.S. Food and Drug Administration (FDA) has approved the use of a new potency testing method for commercial batches of Ryoncil.
Satellos Bioscience (NASDAQ:MSLE) announced that it has received U.S. Food and Drug Administration (FDA) clearance to begin studying forazapadin in patients with facioscapulohumeral muscular dystrophy (FSHD).
Ligand Pharmaceuticals (NASDAQ:LGND) announced a financing agreement with AvenCell Therapeutics that could provide up to $47 million to support development of AvenCell’s cancer treatment pipeline.
IMUNON (NASDAQ:IMNN) presented Phase 2 survival results and Phase 3 enrollment updates for IMNN-001, its investigational therapy for advanced ovarian cancer.
Ainos (NASDAQ:AIMD) announced that it has entered into a VELDONA license agreement with BioPhoenix, establishing a conditional collaboration framework with a potential value of up to $10 million.
